Thus, we argue that the CXCL12/CXCR4 axis activates immunosurveillance via a mechanism (which we name Immunogenic Surrender) that allows tumor identification by innate cells and tumor‐specific T‐cell priming. This evidence concerns the gene CXCL12 and neoplasm.